1694 related articles for article (PubMed ID: 25745043)
21. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
22. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.
Bonella F; Stowasser S; Wollin L
Drug Des Devel Ther; 2015; 9():6407-19. PubMed ID: 26715838
[TBL] [Abstract][Full Text] [Related]
23. The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats.
Gad ES; Salama AAA; El-Shafie MF; Arafa HMM; Abdelsalam RM; Khattab M
Inflammation; 2020 Feb; 43(1):123-134. PubMed ID: 31646446
[TBL] [Abstract][Full Text] [Related]
24. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
25. Nintedanib: from discovery to the clinic.
Roth GJ; Binder R; Colbatzky F; Dallinger C; Schlenker-Herceg R; Hilberg F; Wollin SL; Kaiser R
J Med Chem; 2015 Feb; 58(3):1053-63. PubMed ID: 25474320
[TBL] [Abstract][Full Text] [Related]
26. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
27. Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K/Akt/mTOR Pathway in Mice.
Pan L; Cheng Y; Yang W; Wu X; Zhu H; Hu M; Zhang Y; Zhang M
Inflammation; 2023 Aug; 46(4):1531-1542. PubMed ID: 37160579
[TBL] [Abstract][Full Text] [Related]
28. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
29. Reversion of in vivo fibrogenesis by novel chromone scaffolds.
Kim HS; Yoon YM; Meang MK; Park YE; Lee JY; Lee TH; Lee JE; Kim IH; Youn BS
EBioMedicine; 2019 Jan; 39():484-496. PubMed ID: 30611717
[TBL] [Abstract][Full Text] [Related]
30. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.
Sato S; Shinohara S; Hayashi S; Morizumi S; Abe S; Okazaki H; Chen Y; Goto H; Aono Y; Ogawa H; Koyama K; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
Respir Res; 2017 Sep; 18(1):172. PubMed ID: 28915889
[TBL] [Abstract][Full Text] [Related]
31. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
Huang J; Maier C; Zhang Y; Soare A; Dees C; Beyer C; Harre U; Chen CW; Distler O; Schett G; Wollin L; Distler JHW
Ann Rheum Dis; 2017 Nov; 76(11):1941-1948. PubMed ID: 28814429
[TBL] [Abstract][Full Text] [Related]
32. Fibroblast growth factors and pulmonary fibrosis: it's more complex than it sounds.
Kim KK; Sisson TH; Horowitz JC
J Pathol; 2017 Jan; 241(1):6-9. PubMed ID: 27757968
[TBL] [Abstract][Full Text] [Related]
33. Novel Mechanisms for the Antifibrotic Action of Nintedanib.
Rangarajan S; Kurundkar A; Kurundkar D; Bernard K; Sanders YY; Ding Q; Antony VB; Zhang J; Zmijewski J; Thannickal VJ
Am J Respir Cell Mol Biol; 2016 Jan; 54(1):51-9. PubMed ID: 26072676
[TBL] [Abstract][Full Text] [Related]
34. Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis.
MacKenzie B; Korfei M; Henneke I; Sibinska Z; Tian X; Hezel S; Dilai S; Wasnick R; Schneider B; Wilhelm J; El Agha E; Klepetko W; Seeger W; Schermuly R; Günther A; Bellusci S
Respir Res; 2015 Jul; 16(1):83. PubMed ID: 26138239
[TBL] [Abstract][Full Text] [Related]
35. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA
Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis.
Schmid U; Doege C; Dallinger C; Freiwald M
Pulm Pharmacol Ther; 2018 Feb; 48():136-143. PubMed ID: 29133080
[TBL] [Abstract][Full Text] [Related]
37. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
[TBL] [Abstract][Full Text] [Related]
38. Inflammation and immunity in IPF pathogenesis and treatment.
Heukels P; Moor CC; von der Thüsen JH; Wijsenbeek MS; Kool M
Respir Med; 2019 Feb; 147():79-91. PubMed ID: 30704705
[TBL] [Abstract][Full Text] [Related]
39. FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro.
Joannes A; Brayer S; Besnard V; Marchal-Sommé J; Jaillet M; Mordant P; Mal H; Borie R; Crestani B; Mailleux AA
Am J Physiol Lung Cell Mol Physiol; 2016 Apr; 310(7):L615-29. PubMed ID: 26773067
[TBL] [Abstract][Full Text] [Related]
40. Sustained activation of toll-like receptor 9 induces an invasive phenotype in lung fibroblasts: possible implications in idiopathic pulmonary fibrosis.
Kirillov V; Siler JT; Ramadass M; Ge L; Davis J; Grant G; Nathan SD; Jarai G; Trujillo G
Am J Pathol; 2015 Apr; 185(4):943-57. PubMed ID: 25660181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
